Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
E.E.S. 400 vs ALBAMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
Treatment of infections caused by susceptible strains of microorganisms: respiratory tract infections (including Legionnaires disease, pertussis), skin and soft tissue infections, diphtheria, syphilis, chlamydial infections, and ocular infections in neonates.,Prophylaxis of recurrent rheumatic fever.,Off-label: gastrointestinal motility disorder (as a motilin agonist).
FDA-approved for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) when other agents are not suitable,Off-label: used for severe staphylococcal and enterococcal infections
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Primarily metabolized in the liver via demethylation by CYP3A4; undergoes N-demethylation and hydroxylation.
Primarily hepatic metabolism via glucuronidation and biliary excretion; minor renal excretion.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
70-80% bound to albumin; binding is reversible and saturable at high concentrations.
25-30%, primarily to albumin.
Approximately 0.7 L/kg (range 0.5-0.9 L/kg); indicates extensive tissue penetration including intracellular and inflammatory fluids.
0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid.
Oral (as erythromycin ethylsuccinate): approximately 30-65% (variable, reduced by food); intravenous: 100%.
Oral: 30-40% (variable due to first-pass metabolism); IM: 80-90%; IV: 100%.
No specific dose adjustment required for renal impairment; caution with high doses in severe renal failure (Cr Cl <10 m L/min) due to potential ototoxicity.
GFR 30-89 m L/min: Administer 5-10 mg/kg IV every 12 hours. GFR 15-29 m L/min: Administer 5-10 mg/kg IV every 24 hours. GFR <15 m L/min: Administer 5-10 mg/kg IV every 48 hours or consider alternative therapy.
In hepatic impairment, reduce dose by 50-75% depending on severity. Child-Pugh Class A: no adjustment; Class B: reduce to 50% of normal dose; Class C: avoid or use with extreme caution, maximum 1 g per day.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Use with caution; consider 50% dose reduction.
30-50 mg/kg/day in 4 divided doses. For severe infections, up to 60-100 mg/kg/day. Maximum 2 g/day.
Infants and children: 10 mg/kg IV every 8 hours. Maximum daily dose: 30 mg/kg. Neonates: 10 mg/kg IV every 12 hours.
No specific dose adjustment; monitor for QT prolongation and hearing loss. Consider lower end of dosing range due to age-related decline in hepatic function.
Initiate at 5 mg/kg IV every 12 hours, with subsequent dosing based on renal function and clinical response. Monitor for neurotoxicity and nephrotoxicity.
Increased risk of infantile hypertrophic pyloric stenosis (IHPS) when given to neonates. Erythromycin has also been associated with prolongation of the QT interval and risk of cardiac arrhythmias, including torsades de pointes.
None
Hepatic dysfunction, QT prolongation (risk of arrhythmia), exacerbation of myasthenia gravis, Clostridioides difficile-associated diarrhea, ototoxicity (especially with high doses or renal impairment), potential for drug interactions (CYP3A4 inhibitors/inducers).
Hypersensitivity reactions including anaphylaxis,Hepatotoxicity,Bone marrow suppression (leukopenia, thrombocytopenia),Potential for drug interactions with agents metabolized by CYP450 isoenzymes
Hypersensitivity to erythromycin or any macrolide antibiotic, concomitant use with terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine (risk of cardiac arrhythmias).
Hypersensitivity to novobiocin or any component,Severe hepatic impairment,Breastfeeding (due to potential for kernicterus in neonates)
Take with food to minimize gastrointestinal upset. Avoid grapefruit juice as it can increase erythromycin concentrations via CYP3A4 inhibition. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they may increase ALBAMYCIN levels and risk of toxicity. No other significant food interactions known.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human studies in first trimester. No known risk of major birth defects or miscarriage. Avoid in maternal myasthenia gravis due to potential neonatal hypotonia.
Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless life-threatening. Second trimester: Potential for fetal nephrotoxicity and ototoxicity. Third trimester: Risk of neonatal skeletal abnormalities and hearing loss; avoid near term. Fetal risk outweighs potential benefit.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). No adverse effects reported in infants. Monitor infant for gastrointestinal disturbances or rash.
Excreted in human milk; M/P ratio not reported. Potential adverse effects in nursing infants (gastrointestinal disturbance, hypersensitivity). Use with caution; consider alternative therapy. American Academy of Pediatrics suggests use with caution.
No dose adjustment required. Physiologic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose changes for erythromycin. Standard adult dosing applies.
Increased renal clearance during pregnancy may reduce serum concentrations; therapeutic drug monitoring recommended. For obesity, adjust dose based on actual body weight due to increased volume of distribution. Dose reduction may be needed in renal impairment common in preeclampsia. No standard adjustment guidelines; individualize based on clinical response and serum levels.
E. E. S. 400 (erythromycin ethylsuccinate) is a macrolide antibiotic with bacteriostatic activity. It is a prodrug hydrolyzed to erythromycin base. Use with caution in patients with hepatic impairment or preexisting hearing loss. Monitor for QT prolongation, especially with concurrent use of other QT-prolonging drugs. Commonly used as an alternative in penicillin-allergic patients for respiratory tract infections. It also has prokinetic effects on the GI tract, which can be utilized in gastroparesis but may cause abdominal cramping.
ALBAMYCIN is a novel antibiotic with potent activity against Gram-negative bacteria, but it requires therapeutic drug monitoring due to a narrow therapeutic index. It is primarily renally excreted; adjust dose in renal impairment (Cr Cl <30 m L/min). Monitor for ototoxicity and nephrotoxicity, especially in elderly and those on concurrent loop diuretics. Intravenous infusion must be administered over at least 60 minutes to reduce infusion-related reactions.
Take this medication exactly as prescribed, usually every 6 hours or as directed.,Complete the full course even if you feel better to prevent resistance.,May cause stomach upset; taking with food can reduce GI irritation.,Avoid grapefruit juice as it may affect drug levels.,Report symptoms of liver problems (yellowing skin/eyes, dark urine) or hearing loss immediately.,Do not take with certain medications like statins or warfarin without consulting your doctor.,Use effective contraception if applicable, as erythromycin may reduce birth control pill efficacy.
Take ALBAMYCIN exactly as prescribed; do not miss doses.,Complete the full course even if you feel better.,Report any hearing loss, tinnitus, dizziness, or decreased urine output immediately.,Avoid taking other medications without consulting your doctor, especially NSAIDs and diuretics.,Stay well-hydrated during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about E.E.S. 400 vs ALBAMYCIN, answered by our medical review team.
E.E.S. 400 is a Macrolide Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.. ALBAMYCIN is a Macrolide Antibiotic that works by Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between E.E.S. 400 and ALBAMYCIN depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of E.E.S. 400 is: Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.. The standard adult dose of ALBAMYCIN is: 5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between E.E.S. 400 and ALBAMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. E.E.S. 400 is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human studies in first trimester. No known risk of major birth defects or miscarriage. Avoid i. ALBAMYCIN is classified as Category C. Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.